Why is the Spire Healthcare share price up 25% today?

The Spire Healthcare share is a big gainer in today’s trading, but the question is whether it’s a good investment to make?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

UK-based hospital group Spire Healthcare (LSE: SPI) is one of the biggest FTSE gainers today. As I write, its share price is up 25% from yesterday’s close, the highest levels seen since August 2018.

Why has the share price risen?

The sharp upturn follows the proposed acquisition of the company by Australia’s Ramsay Health Care at an offer of 240p per share. To give some perspective, yesterday’s closing price was 193p. In today’s trading, the company’s share price has quickly risen beyond this offer price to 244p. 

If I were looking at these numbers today, it would make sense to buy the share at levels lower than the offer price, which could earn some assured returns in the foreseeable future.

What happens now 

However, that is only if the deal does go through. It may not. There are already reports that institutional shareholders are disappointed with the offer price. According to a Sky News report, they want to push the price up to 400p. 

If the two groups are in negotiations, then it is possible that the Spire Healthcare share price will rise even higher. But that is all just speculation. And at the Motley Fool, we believe in long-term investing. 

So, the company is of interest to me only if the deal does not go through and there is no more likelihood of a sell-out. To assess if it is indeed a stock I’d like to buy (or not), I looked at the financials first. 

Financials affected, but good outlook

The full-year 2020 was pretty bad for it as elective surgeries were suspended and its contracts with the NHS meant that all its capacity was made available to the service. As a result, its revenues declined by 6.2% from the year before and it ran up an operating loss of £146m. 

This is in sharp contrast to its growing revenue in 2019 and an operating profit of £94m. This, however, gives me hope that it can bounce back as the pandemic recedes. This hope is also bolstered by its performance in the second half of 2020, which showed a revenue increase of 5.9% from the year before.

Also, there are signs of healthy demand in 2021. For instance, its private enquiries are higher than in last year and there is a waiting list for private surgeries, among others.  

Reduced debt

Notably, Spire Healthcare’s net bank debt actually reduced during the year because of advance payments received on its NHS contracts, measured capital spending, and suspension of its final dividend. This is a particular positive in my view, at a time when companies have actually racked up debt. 

My takeaway

All of this matters, however, only if the company’s acquisition does not go through. For now, I think it is a good idea for me to wait and watch how things progress. If it does not, the Spire Healthcare share does merit consideration.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »